These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 24613115)
1. Hep par-1: a novel immunohistochemical marker for differentiating hepatocellular carcinoma from metastatic carcinoma. Hanif R; Mansoor S J Coll Physicians Surg Pak; 2014 Mar; 24(3):186-9. PubMed ID: 24613115 [TBL] [Abstract][Full Text] [Related]
2. Utilization of antihepatocyte clone OCH1E5 (Hep Par 1) in histological evaluation of liver tumors. Amarapurkar AD; Rege JD; Joshi AS; Vaiphei K; Amarapurkar DN Indian J Pathol Microbiol; 2006 Jul; 49(3):341-4. PubMed ID: 17001880 [TBL] [Abstract][Full Text] [Related]
3. The utility of hepatocyte paraffin 1 antibody in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma and metastatic carcinoma. Shiran MS; Isa MR; Sherina MS; Rampal L; Hairuszah I; Sabariah AR Malays J Pathol; 2006 Dec; 28(2):87-92. PubMed ID: 18376797 [TBL] [Abstract][Full Text] [Related]
4. Immunohistological evaluation of single small hepatocellular carcinoma with negative staining of monoclonal antibody Hepatocyte Paraffin 1. Sugiki T; Yamamoto M; Aruga A; Takasaki K; Nakano M J Surg Oncol; 2004 Nov; 88(2):104-7. PubMed ID: 15499598 [TBL] [Abstract][Full Text] [Related]
5. Hep Par 1 and selected antibodies in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma, combined tumours and metastatic carcinoma. Leong AS; Sormunen RT; Tsui WM; Liew CT Histopathology; 1998 Oct; 33(4):318-24. PubMed ID: 9822920 [TBL] [Abstract][Full Text] [Related]
6. Comparative immunohistochemical profile of hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma. Lau SK; Prakash S; Geller SA; Alsabeh R Hum Pathol; 2002 Dec; 33(12):1175-81. PubMed ID: 12514785 [TBL] [Abstract][Full Text] [Related]
7. Glypican-3 is useful but not superior to Hep Par 1 in differentiating hepatocellular carcinoma from other liver tumours. Pour AM; Masir N; Rose IM Malays J Pathol; 2016 Dec; 38(3):229-233. PubMed ID: 28028292 [TBL] [Abstract][Full Text] [Related]
9. Comparison of 5 Immunohistochemical Markers of Hepatocellular Differentiation for the Diagnosis of Hepatocellular Carcinoma. Nguyen T; Phillips D; Jain D; Torbenson M; Wu TT; Yeh MM; Kakar S Arch Pathol Lab Med; 2015 Aug; 139(8):1028-34. PubMed ID: 26230595 [TBL] [Abstract][Full Text] [Related]
10. The diagnostic value of arginase-1 immunostaining in differentiating hepatocellular carcinoma from metastatic carcinoma and cholangiocarcinoma as compared to HepPar-1. Radwan NA; Ahmed NS Diagn Pathol; 2012 Oct; 7():149. PubMed ID: 23111165 [TBL] [Abstract][Full Text] [Related]
11. Immunoreactivity of Hep Par 1 in hepatic and extrahepatic tumors and its correlation with albumin in situ hybridization in hepatocellular carcinoma. Kakar S; Muir T; Murphy LM; Lloyd RV; Burgart LJ Am J Clin Pathol; 2003 Mar; 119(3):361-6. PubMed ID: 12645337 [TBL] [Abstract][Full Text] [Related]
12. Hepatocyte paraffin 1 expression in human normal and neoplastic tissues: tissue microarray analysis on 3,940 tissue samples. Lugli A; Tornillo L; Mirlacher M; Bundi M; Sauter G; Terracciano LM Am J Clin Pathol; 2004 Nov; 122(5):721-7. PubMed ID: 15491968 [TBL] [Abstract][Full Text] [Related]
13. Hep par 1 antibody stain for the differential diagnosis of hepatocellular carcinoma: 676 tumors tested using tissue microarrays and conventional tissue sections. Fan Z; van de Rijn M; Montgomery K; Rouse RV Mod Pathol; 2003 Feb; 16(2):137-44. PubMed ID: 12591966 [TBL] [Abstract][Full Text] [Related]
14. Cutaneous metastasis of hepatocellular carcinoma diagnosed by fine needle aspiration cytology and Hep Par 1 immunopositivity. Isa NM; Bong JJ; Ghani FA; Rose IM; Husain S; Azrif M Diagn Cytopathol; 2012 Nov; 40(11):1010-4. PubMed ID: 21563319 [TBL] [Abstract][Full Text] [Related]
15. MOC-31 aids in the differentiation of metastatic adenocarcinoma from hepatocellular carcinoma. Niemann TH; Hughes JH; De Young BR Cancer; 1999 Oct; 87(5):295-8. PubMed ID: 10536355 [TBL] [Abstract][Full Text] [Related]
16. Diagnostic accuracy of glypican-3 in differentiating hepatocellular carcinoma from metastatic liver tumours. Majeed S; Mushtaq S; Azam M; Akhtar N; Hussain M; Loya A J Pak Med Assoc; 2018 Jul; 68(7):1029-1031. PubMed ID: 30317296 [TBL] [Abstract][Full Text] [Related]
17. Histologic differentiation of hepatocellular carcinoma from adenocarcinoma by a simple panel: evaluation of the pitfalls. Geramizadeh B; Boub R; Rahsaz M Indian J Pathol Microbiol; 2007 Jul; 50(3):507-10. PubMed ID: 17883119 [TBL] [Abstract][Full Text] [Related]
18. Role of CD10 immunochemistry in differentiating hepatocellular carcinoma from metastatic carcinoma of the liver. Ahuja A; Gupta N; Kalra N; Srinivasan R; Chawla Y; Rajwanshi A Cytopathology; 2008 Aug; 19(4):229-35. PubMed ID: 18070122 [TBL] [Abstract][Full Text] [Related]
19. Hepatocyte antigen as a marker of hepatocellular carcinoma: an immunohistochemical comparison to carcinoembryonic antigen, CD10, and alpha-fetoprotein. Chu PG; Ishizawa S; Wu E; Weiss LM Am J Surg Pathol; 2002 Aug; 26(8):978-88. PubMed ID: 12170084 [TBL] [Abstract][Full Text] [Related]
20. Immunoreactivity for hepatocyte paraffin 1 antibody in hepatoid adenocarcinomas of the gastrointestinal tract. Maitra A; Murakata LA; Albores-Saavedra J Am J Clin Pathol; 2001 May; 115(5):689-94. PubMed ID: 11345832 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]